Rethinking the war on cancer

The Lancet

Volumn 383, Issue 9916, 2014, Pages 558-563

  Hanahan, Douglas ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARMY; ARTICLE; CANCER RESEARCH; GEOGRAPHY; HUMAN; MEDICAL SPECIALIST; NEOPLASM; PRIORITY JOURNAL; WAR;

EID: 84895909846     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62226-6     Document Type: Review

References (30)

1. The US National Cancer Act of 1971 (http://legislative.cancer.gov/ history/phsa/1971) (accessed Dec 11, 2013).
2. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet 2013; published online Dec 16. http://dx.doi.org/10.1016/S0140-6736(13)62224-2.
3. Coleman MP. Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet 2013; published online Dec 16. http://dx.doi.org/10.1016/S0140-6736(13)62225-4.
4. Cavalli F. An appeal to world leaders: stop cancer now. Lancet 2013; 381: 425-26.
5. Varmus H, Kumar HS. Addressing the growing international challenge of cancer: a multinational perspective. Sci Transl Med 2013, 5: 175cm2.
6. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013; 14: 1165-74.
7. Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 2004; 149: 76-82, 84-86, 88 passim.
8. Leaf C. The truth in small doses: Why we're losing the war on cancer - and how to win it. Simon and Schuster, New York, 2013.
9. Vogelstein B, Kinzler KW. Winning the war: science parkour. Sci Transl Med 2012, 4: 127ed2.
10. Johnson SE, Libicki MC, eds. Dominant Battlespace Knowledge. National Defense University Press 1995. http://www.dtic.mil/dtic/tr/fulltext/u2/a311041. pdf (accessed Dec 11, 2013).
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
13. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012; 4: 127ps8.
14. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
15. Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 2012; 8: 999-1014.
16. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108: 479-85.
17. Garraway LA, Jänne PA. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012; 2: 214-26.
18. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
19. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
20. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012; 30: 4026-34.
21. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30: 679-92.
22. Bock C, Lengauer T. Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 2012; 12: 494-501.
23. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013; 339: 286-91.
24. Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010; 7: 718-24.
25. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011; 10: 351-64.
26. Roulston A, Muller WJ, Shore GC. BIM, PUMA, and the Achilles' heel of oncogene addiction. Sci Signal 2013; 6: pe12.
27. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-22.
28. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treat Rev 2012; 38: 589-98.
29. Togo S, Polanska UM, Horimoto Y, Orimo A. Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers 2013; 5: 149-69.
30. De Palma M, Hanahan D. The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol 2012; 6: 111-27.